Literature DB >> 22228322

An empirically validated responder definition for the reduction of moderate to severe hot flushes in postmenopausal women.

Christoph Gerlinger1, Kerstin Gude, Florian Hiemeyer, Thomas Schmelter, Matthias Schäfers.   

Abstract

OBJECTIVE: The aim of this study was to derive an empirically validated definition of treatment responders for the reduction of moderate to severe hot flushes in postmenopausal women.
METHODS: This study used prospective blinded data analysis from a placebo-controlled study to investigate the efficacy of a treatment of moderate to severe hot flushes in postmenopausal women. Seven hundred ten postmenopausal women with at least 50 moderate to severe hot flushes per week participated in the study. The participants recorded the number of moderate to severe hot flushes each day in a diary. They also assessed their satisfaction with treatment on a Clinical Global Impression-improvement rating scale. Changes in the weekly number of moderate to severe hot flushes were compared with participants' self-assessments to derive an empirically validated minimal clinically important difference. This anchor-based value was compared with the conventional half-SD rule for minimal clinically important difference in participant-reported outcomes.
RESULTS: Anchor- and distribution-based minimal clinically important differences between "no change/worse" and "minimally improved" were an absolute reduction of 19.1 and 18.6 in the weekly number of moderate to severe hot flushes, respectively. In addition, the threshold between "minimally improved" compared with "much improved or better" was determined, based on the anchor method, as an absolute reduction of 40.3 in the weekly number of moderate to severe hot flushes.
CONCLUSIONS: A responder was defined as having at least an improvement of 19.1 hot flushes per week at week 4 and an improvement of 40.3 hot flushes per week at week 12.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22228322     DOI: 10.1097/gme.0b013e31823de8ba

Source DB:  PubMed          Journal:  Menopause        ISSN: 1072-3714            Impact factor:   2.953


  2 in total

1.  Evaluation of clinical meaningfulness of estrogen plus progesterone oral capsule (TX-001HR) on moderate to severe vasomotor symptoms.

Authors:  Ginger D Constantine; Dennis A Revicki; Risa Kagan; James A Simon; Shelli Graham; Brian Bernick; Sebastian Mirkin
Journal:  Menopause       Date:  2019-05       Impact factor: 2.953

2.  TX-001HR is associated with a clinically meaningful effect on severity of moderate to severe vasomotor symptoms in the REPLENISH trial.

Authors:  Ginger D Constantine; James A Simon; Andrew M Kaunitz; James H Pickar; Dennis A Revicki; Shelli Graham; Brian Bernick; Sebastian Mirkin
Journal:  Menopause       Date:  2020-11       Impact factor: 3.310

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.